ID

23348

Beskrivning

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Nyckelord

  1. 2017-07-02 2017-07-02 -
Rättsinnehavare

Genentech, Inc.

Uppladdad den

2 juli 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

Patient administration
Beskrivning

Patient administration

Subject Number
Beskrivning

PT

Datatyp

integer

Alias
UMLS CUI [1]
C2348585
Subject Initials:
Beskrivning

PTINIT

Datatyp

text

Alias
UMLS CUI [1,1]
C1997894
UMLS CUI [1,2]
C2986440
Report Date:
Beskrivning

VDT

Datatyp

date

Alias
UMLS CUI [1,1]
C1302584
TREATMENT CROSSOVER (UNSCHEDULED)
Beskrivning

TREATMENT CROSSOVER (UNSCHEDULED)

Did the subject participate in the treatment crossover plan?
Beskrivning

CROSSOVER_PARTICIPAT [CRSRPAR]

Datatyp

boolean

Alias
UMLS CUI [1]
C0150097
Indicate the visit month at which the subject’s treatment crossover was implemented:
Beskrivning

If Yes:

Datatyp

integer

Were both early crossover criteria listed below met?
Beskrivning

If the crossover visit month was prior to the Month 25 visit, complete the following: • Has lost >=10 letters on EDTRS BCVA from Baseline due to DME, as confirmed on >= 2 consecutive scheduled study visits, and • OCT images confirm persistent edema (CFT 250 μm) at the same visits.

Datatyp

boolean

Alias
UMLS CUI [1]
C0242801
Indicate the reason why the subject did not participate in the treatment crossover:
Beskrivning

If No:

Datatyp

integer

Alias
UMLS CUI [1]
C0680251
Other (specify):
Beskrivning

REASON_TREAT_CRSOVR [NCRSVR]

Datatyp

text

Alias
UMLS CUI [1]
C0680251

Similar models

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Patient administration
PT
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
PTINIT
Item
Subject Initials:
text
C1997894 (UMLS CUI [1,1])
C2986440 (UMLS CUI [1,2])
VDT
Item
Report Date:
date
C1302584 (UMLS CUI [1,1])
Item Group
TREATMENT CROSSOVER (UNSCHEDULED)
CROSSOVER_PARTICIPAT [CRSRPAR]
Item
Did the subject participate in the treatment crossover plan?
boolean
C0150097 (UMLS CUI [1])
TRT_CRSOVR_IMP_MTH [RXCOMO]
Item
Indicate the visit month at which the subject’s treatment crossover was implemented:
integer
ELIGIBILITY_CRITERIA [ELIGCR]
Item
Were both early crossover criteria listed below met?
boolean
C0242801 (UMLS CUI [1])
Item
Indicate the reason why the subject did not participate in the treatment crossover:
integer
C0680251 (UMLS CUI [1])
Code List
Indicate the reason why the subject did not participate in the treatment crossover:
CL Item
Subject has discontinued study treatment (1)
CL Item
Subject refused to participate in the treatment crossover plan (2)
CL Item
Other (specify): (3)
REASON_TREAT_CRSOVR [NCRSVR]
Item
Other (specify):
text
C0680251 (UMLS CUI [1])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial